Leerink Partners Increases Insulet (NASDAQ:PODD) Price Target to $386.00

Insulet (NASDAQ:PODD) had its price objective raised by research analysts at Leerink Partners from $385.00 to $386.00 in a research report issued to clients and investors on Friday,MarketScreener reports. The brokerage currently has an “outperform” rating on the medical instruments supplier’s stock. Leerink Partners’ target price indicates a potential upside of 16.56% from the company’s previous close.

Several other analysts also recently issued reports on PODD. Rothschild & Co Redburn boosted their price target on Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of Insulet in a report on Wednesday, October 8th. Jefferies Financial Group raised their price target on shares of Insulet from $375.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. UBS Group upgraded shares of Insulet from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $355.00 to $400.00 in a research note on Wednesday. Finally, Piper Sandler increased their target price on shares of Insulet from $320.00 to $360.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $379.45.

Insulet Price Performance

Shares of PODD opened at $331.17 on Friday. The company’s 50-day moving average is $322.22 and its 200-day moving average is $315.08. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The firm has a market capitalization of $23.30 billion, a PE ratio of 100.66, a PEG ratio of 2.64 and a beta of 1.39. Insulet has a fifty-two week low of $230.05 and a fifty-two week high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. The business had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. Insulet’s quarterly revenue was up 29.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.08 EPS. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities analysts forecast that Insulet will post 3.92 EPS for the current year.

Insiders Place Their Bets

In other news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Prem Singh sold 687 shares of the business’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.39% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in PODD. Norges Bank bought a new stake in shares of Insulet during the 2nd quarter valued at approximately $324,689,000. Qube Research & Technologies Ltd acquired a new stake in Insulet in the second quarter valued at approximately $131,439,000. American Century Companies Inc. grew its stake in shares of Insulet by 34.8% during the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock worth $302,686,000 after buying an additional 297,734 shares during the last quarter. Nuveen LLC acquired a new position in shares of Insulet during the first quarter worth $74,163,000. Finally, Worldquant Millennium Advisors LLC bought a new position in shares of Insulet in the 2nd quarter valued at $80,082,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.